NDC 72934-1027

BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%

Brimonidine Tartrate 0.25% / Potassium Azeloyl Diglycinate 8%

BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8% is a Topical Gel in the Human Prescription Drug category. It is labeled and distributed by Sincerus Florida, Llc. The primary component is Brimonidine Tartrate.

Product ID72934-1027_88ef2cc1-1856-9606-e053-2995a90a2e67
NDC72934-1027
Product TypeHuman Prescription Drug
Proprietary NameBRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8%
Generic NameBrimonidine Tartrate 0.25% / Potassium Azeloyl Diglycinate 8%
Dosage FormGel
Route of AdministrationTOPICAL
Marketing Start Date2019-05-16
Marketing CategoryUNAPPROVED DRUG OTHER / UNAPPROVED DRUG OTHER
Labeler NameSincerus Florida, LLC
Substance NameBRIMONIDINE TARTRATE
Active Ingredient Strength0 g/100g
Pharm ClassesAdrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 72934-1027-2

30 g in 1 BOTTLE, PUMP (72934-1027-2)
Marketing Start Date2019-05-16
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 72934-1027-2 [72934102702]

BRIMONIDINE TARTRATE 0.25% / POTASSIUM AZELOYL DIGLYCINATE 8% GEL
Marketing Categoryunapproved drug other
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2019-05-16

Drug Details

Active Ingredients

IngredientStrength
BRIMONIDINE TARTRATE.25 g/100g

OpenFDA Data

SPL SET ID:88ef2cc1-1855-9606-e053-2995a90a2e67
Manufacturer
UNII

Pharmacological Class

  • Adrenergic alpha-Agonists [MoA]
  • alpha-Adrenergic Agonist [EPC]
  • Adrenergic alpha-Agonists [MoA]
  • alpha-Adrenergic Agonist [EPC]

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.